"Boehringer Ingelheim, a global leader in animal health, announced that Semintra 4 mg/ml oral solution is now available in Europe to manage both chronic kidney disease and hypertension in cats. First approved in 2013 for the reduction of proteinuria associated with chronic kidney disease in cats, Semintra 4 mg/ml oral solution is now launched to also treat systemic hypertension in cats.
Chronic kidney disease and hypertension are very common and closely connected conditions in aging cats. Both conditions silently and progressively diminish a cat’s quality and length of life, with clinical signs only visible in later disease stages. However, with regular exams, veterinarians can help identify earlier disease stages and recommend appropriate treatment.
Semintra 4 mg/ml oral solution is the only feline medication approved to manage chronic kidney disease and hypertension individually or in combination. With a proven history of clinical safety and efficacy, Semintra 4 mg/ml oral solution offers a fast and sustained reduction in proteinuria and blood pressure, which may help restore balance to the kidneys and support the cat’s appetite, activity levels, and quality of life.
“Kidney disease and high blood pressure can fuel each other in a severe cycle, negatively impacting quality of life for cats and their owners,” said Dr. Erich Schött, head of pet therapeutics and pet vaccines at Boehringer Ingelheim. “With both claims in one product we can now offer a simple solution for these common and complex conditions. Semintra 4 mg/ml oral solution is easy to give, well-accepted by cats, and most importantly, it may help promote a better quality of life for our cherished feline companions.”
Semintra 4 mg/ml, designed specifically for cats, is delivered into a cat’s mouth or on top of food once a day with a ml-calibrated syringe. The new product packaging now includes a QR code leading to a digital leaflet with detailed product information and an animated “how-to-use” video, as well as a printed leaflet, designed to enhance the pet owner’s experience.
Chronic kidney disease affects up to 30 - 50% of senior cats, which considered to be 7 to 10 years and older, and up to 65% of them also have hypertension.
Hypertension affects 20 - 40% of senior cats, and up to 74% of them also have chronic kidney disease.
Clinical signs of chronic kidney disease do not appear until the cat has lost at least 67% of kidney function.
International guidelines recommend regular clinic assessment and screening of cats over 7 years of age for chronic diseases (including chronic kidney disease and hypertension).
Boehringer Ingelheim provides first-in-class innovation for preventing and treating diseases in animals. The company offers a wide range of vaccines, parasite-control products, and medicines for pets, horses, and livestock to veterinarians, animal owners, farmers, and governments. As a leader in animal health, Boehringer Ingelheim values that the health of humans and animals is deeply connected and strives to make a difference for people, animals, and society.